ISSN: 0732-183X

Journal of Clinical Oncology Q1 Unclaimed

American Society of Clinical Oncology United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.

Type: Journal

Type of Copyright: CC BY-NC-ND

Languages: English

Open Access Policy: Open Access

Type of publications:

Publication frecuency: -

Categories: Cancer Research (Q1) Medicine (miscellaneous) (Q1) Oncology (Q1)

Price

3166 €

Gold OA

-

Green OA

- €

Non OA

Metrics

10,054

SJR Impact factor

525

H Index

574

Total Docs (Last Year)

2341

Total Docs (3 years)

14282

Total Refs

26112

Total Cites (3 years)

1352

Citable Docs (3 years)

19,71

Cites/Doc (2 years)

24,88

Ref/Doc

Aims and Scope

Cancer Tumor Oncology research Medicine

Other journals with similar parameters

Accounts of Chemical Research Q1
Annual Review of Pathology: Mechanisms of Disease Q1
The Lancet Global Health Q1
Journal of Experimental Medicine Q1
Annual Review of Clinical Psychology Q1

Best articles

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.

ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.

Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma

Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry.

Breast Cancer Screening in Women Previously Treated for Hodgkin's Disease: A Prospective Cohort Study

Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.

SHOW MORE ARTICLES

Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study

Classical Hodgkin's Disease and Follicular Lymphoma Originating From the Same Germinal Center B Cell

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease.

Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators

Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group.

Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.

Comments

No comments ... Be the first to comment!

Publication speed

Review quality

Edition and editorial team

Paper Link

Attach one of your papers. We need to confirm that you have had a relation with this journal in order to review its service.